June 24, 2015

Drug Caucus Hearing on Barriers to Cannabidiol Research

The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy.

Opening Statements


Chuck Grassley

Sen. Grassley’s opening statement, as prepared for delivery.


Dianne Feinstein

Sen. Feinstein’s opening statement, as prepared for delivery.


Mr. Joseph Rannazzisi

Deputy Assistant Administrator of Drug Diversion with the Drug Enforcement Administration (DEA), Washington, D.C.

Dr. Douglas Throckmorton

Deputy Director for the Center for Drug Evaluation and Research, Food and Drug Administration, Washington, D.C.

Dr. Nora Volkow

Director, National Institute on Drug Abuse, Washington, D.C.

Panel II

Dr. John “Brad” Ingram

Child Neurologist, University of Mississippi Medical Center, Jackson, Mississippi

Dr. Tom Minahan

Emergency Room Physician, Arrowhead Regional Medical Center, Colton, California

Dr. Kevin Sabet

Co-Founder, Project SAM (Smart Approaches to Marijuana), Cambridge, Massachusetts